223TiP EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Petrylak D, Rosenberg J, Lee J, Yonese J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A, Powles T. 223TiP EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma. Annals Of Oncology 2019, 30: ix75-ix76. DOI: 10.1093/annonc/mdz425.014.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaSeattle GeneticsUrothelial carcinomaDisease progressionCohort 1Microtubule-disrupting agent monomethyl auristatin EDay 1Prior platinum-containing chemotherapyClinical care optionsRadiological disease progressionSafety/tolerabilityTumour response statusPlatinum-containing chemotherapyPhase 2 studyPhase 3 trialPhase III trialsSanofi-AventisPlatinum-based chemotherapyCurrent treatment optionsIndependent central reviewHumanized monoclonal antibodyMonomethyl auristatin ELower survival rateMedian DoRPrimary endpoint